Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXDX Accelerate Diagnostics		$0.65	$0.03 ▼ $2.09	$857K	0.22	535,059 shs	53.64 million shs
EYPT Eyepoint Pharmaceuticals	$9.95 +4.8%	$7.79	$3.91 ▼ $13.99	$653.02M	1.67	818,516 shs	1.30 million shs
FLDM Fluidigm		$3.66	$2.67 ▼ $7.51	$283.76M	1.14	968,838 shs	60,126 shs
HBIO Harvard Bioscience	$0.46 +3.5%	$0.42	$0.28 ▼ $3.60	$19.59M	1.52	3.16 million shs	635,110 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXDX Accelerate Diagnostics	0.00%	0.00%	0.00%	-93.21%	-96.54%
EYPT Eyepoint Pharmaceuticals	+4.85%	+4.19%	+11.30%	+117.72%	+14.63%
FLDM Fluidigm	0.00%	0.00%	0.00%	0.00%	0.00%
HBIO Harvard Bioscience	+3.45%	+2.21%	+12.08%	-0.15%	-83.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXDX Accelerate Diagnostics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	2.6844 of 5 stars	3.5	3.0	0.0	0.0	3.3	1.7	0.0
FLDM Fluidigm	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HBIO Harvard Bioscience	4.1148 of 5 stars	3.3	4.0	0.0	4.5	0.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXDX Accelerate Diagnostics	4.00	Strong Buy	N/A	N/A
EYPT Eyepoint Pharmaceuticals	3.00	Buy	$25.67	157.96% Upside
FLDM Fluidigm	0.00	N/A	N/A	N/A
HBIO Harvard Bioscience	2.50	Moderate Buy	$3.00	554.59% Upside

Current Analyst Ratings Breakdown

Latest HBIO, EYPT, AXDX, and FLDM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	EYPT Eyepoint Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$28.00
5/29/2025	EYPT Eyepoint Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
5/16/2025	EYPT Eyepoint Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $26.00
5/13/2025	HBIO Harvard Bioscience	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Speculative Buy ➝ Speculative Buy	$4.50 ➝ $3.00
5/8/2025	EYPT Eyepoint Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $27.00
4/9/2025	HBIO Harvard Bioscience	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Sector Weight

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXDX Accelerate Diagnostics	$11.70M	0.00	N/A	N/A	($1.37) per share	0.00
EYPT Eyepoint Pharmaceuticals	$43.27M	15.82	N/A	N/A	$4.93 per share	2.02
FLDM Fluidigm	$130.58M	0.00	N/A	N/A	$1.24 per share	0.00
HBIO Harvard Bioscience	$94.14M	0.22	$0.10 per share	4.39	$1.45 per share	0.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXDX Accelerate Diagnostics	-$61.62M	-$2.34	N/A	N/A	N/A	-471.83%	N/A	-191.66%	N/A
EYPT Eyepoint Pharmaceuticals	-$130.87M	-$2.41	N/A	N/A	N/A	-261.91%	-54.27%	-41.75%	8/6/2025 (Estimated)
FLDM Fluidigm	-$59.24M	-$0.78	N/A	N/A	N/A	-45.36%	-40.15%	-14.86%	N/A
HBIO Harvard Bioscience	-$12.40M	-$1.32	N/A	∞	N/A	-63.51%	-4.96%	-2.24%	8/14/2025 (Estimated)

Latest HBIO, EYPT, AXDX, and FLDM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	EYPT Eyepoint Pharmaceuticals	-$0.67	N/A	N/A	N/A	$6.82 million	N/A
5/7/2025	Q1 2025	EYPT Eyepoint Pharmaceuticals	-$0.65	-$0.65	N/A	-$0.65	$8.84 million	$24.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXDX Accelerate Diagnostics	N/A	N/A	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FLDM Fluidigm	N/A	N/A	N/A	N/A	N/A
HBIO Harvard Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXDX Accelerate Diagnostics	N/A	1.50	1.34
EYPT Eyepoint Pharmaceuticals	N/A	7.85	7.79
FLDM Fluidigm	0.68	1.45	1.03
HBIO Harvard Bioscience	N/A	0.81	0.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXDX Accelerate Diagnostics	17.14%
EYPT Eyepoint Pharmaceuticals	99.41%
FLDM Fluidigm	76.59%
HBIO Harvard Bioscience	80.87%

Insider Ownership

Company	Insider Ownership
AXDX Accelerate Diagnostics	43.60%
EYPT Eyepoint Pharmaceuticals	4.46%
FLDM Fluidigm	2.90%
HBIO Harvard Bioscience	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXDX Accelerate Diagnostics	220	25.21 million	14.13 million	Optionable
EYPT Eyepoint Pharmaceuticals	120	68.81 million	65.74 million	Optionable
FLDM Fluidigm	615	76.49 million	74.27 million	Optionable
HBIO Harvard Bioscience	490	44.21 million	40.01 million	Optionable

HBIO, EYPT, AXDX, and FLDM Headlines

Recent News About These Companies

Harvard, Other Ivies With Healthy Endowments Face Hefty New Taxes With Passage of Trump’s Signature Spending Bill

July 8 at 9:05 PM | nysun.comN

Trinity College appoints Harvard dean, former UConn official as new VP and CFO

July 8 at 9:05 PM | newstimes.comN

If your partner uses any of these 7 phrases every day, it means they ‘truly trust' you: Harvard-trained psychologist

July 8 at 9:05 PM | nbclosangeles.comN

Harvard, other Ivies hit with endowment tax hike in Trump spending bill

July 8 at 9:05 PM | msn.com

Research institute, affiliated with Harvard and MIT, lays off 75

July 8 at 9:05 PM | msn.com

Harvard-MIT Broad Institute slashes 75 jobs and $42M budget amid US federal funding crisis

July 8 at 10:51 AM | msn.com

How Harvard’s Ties to China Helped Make It a White House Target

July 7 at 7:38 AM | nytimes.com

Columbia tried to negotiate with the Trump administration. Here’s what Harvard can learn from its efforts.

July 7 at 2:37 AM | bostonglobe.comB

Harvard professor union will ‘strongly’ oppose any deal between school and Trump, members say

July 6 at 9:36 PM | bostonglobe.comB

‘Avoid Boston, watch what you post on social media’: Harvard issues travel warning to international students

July 6 at 11:33 AM | financialexpress.comF

Trump Again Says Harvard Deal Is Likely, 2 Weeks After Talks Became Public

July 6 at 2:19 AM | thecrimson.comT

Trump Signs Spending Package Into Law, Imposing 8% Tax on Harvard’s Endowment Income

July 5, 2025 | thecrimson.comT

Ex-Massachusetts State Police trooper sues Harvard for not being promoted ‘because of his age’

July 4, 2025 | msn.com

Harvard neuroscientist’s bizarre brain hacks might be your key to peak mental health

July 4, 2025 | economictimes.indiatimes.com

Trump Administration Declares Harvard in ‘Violent Violation’ of Civil Rights Act—Threatens Loss of Tax-Exempt Status and $500 Million Tax Bill

July 4, 2025 | sfgate.com

Harvard’s Battle With Trump Admin May Break It

July 4, 2025 | ijr.comI

Harvard Staff Warn International Students of Airport Searches, Social Media Screening

July 4, 2025 | thecrimson.comT

Harvard’s battle with Trump could could cost it $1 billion a year

July 4, 2025 | msn.com

Trump’s antisemitism probe mostly relies on Harvard’s own report, Harvard claims

July 3, 2025 | masslive.comM

Read the Trump admin letter threatening to cut all of Harvard’s funding

July 3, 2025 | masslive.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO, EYPT, AXDX, and FLDM Company Descriptions

Accelerate Diagnostics NASDAQ:AXDX

$0.04 +0.04 (+∞)

As of 05/14/2025

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Eyepoint Pharmaceuticals NASDAQ:EYPT

$9.95 +0.46 (+4.85%)

Closing price 07/8/2025 04:00 PM Eastern

Extended Trading

$9.91 -0.04 (-0.40%)

As of 07/8/2025 06:36 PM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Fluidigm NASDAQ:FLDM

Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Harvard Bioscience NASDAQ:HBIO

$0.46 +0.02 (+3.45%)

Closing price 07/8/2025 04:00 PM Eastern

Extended Trading

$0.46 0.00 (-0.07%)

As of 07/8/2025 07:50 PM Eastern

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time